Shares of Syros Pharmaceuticals, Inc. (SYRS) are down over 44% in premarket trading following the news that the company will voluntarily delist its common stock from the Nasdaq Stock Market and deregister with the U.S. Securities and Exchange Commission.
Syros Pharmaceuticals made the decision after failing to meet Nasdaq's listing standards and facing ongoing financial difficulties.
The company's stock price had remained below $1.00 per share for an extended period, and it also failed to meet Nasdaq's requirements for market value and publicly held shares.
Additionally, the failure of the company's SELECT-MDS-1 Phase 3 clinical trial for its drug tamibarotene, which did not meet its primary endpoint, played a significant role in the decision.
As a result, Syros has been focusing on winding down its operations and limiting expenditures.
By delisting and deregistering, Syros aims to reduce its regulatory costs and conserve cash to fund the wind-down process. This move will also relieve the company from ongoing SEC reporting obligations, helping to preserve its financial resources.
The delisting process is expected to be completed by March 20, 2025. SYRS closed Friday's (Feb.28 2025) trading at $0.14, down by 0.83 percent. In premarket trading Monday, the stock is down by 44.13 percent at $0.08 on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
April 10, 2026 16:21 ET Inflation data from the U.S. was the main data event this week as the conflict in the Middle East continue. The minutes of the latest Fed policy session and the survey data on the services sector also made headlines. In Europe, manufacturing orders data from Germany was in focus. Price data from China drew attention in Asia.